Lack of biomarkers to predict response to drug in clinical trials | Lack of diagnostic, predictive and prognostic biomarkers for lupus | Less effective management of lupus due to social determinants of health in predominantly lower socioeconomic status areas |
Lack of user-friendly, sensitive and accurate outcome measures | Lack of treatment adherence | Lack of patient access to clinical lupus experts |
Suboptimal clinical trial design and outcome measures for patients across age groups | Limited awareness and understanding of lupus among non-expert medical professionals | Lack of access to medications either due to lack of coverage or added cost to patients |